STAR Q1 FY27 Results & Earnings Analysis
Sentiment: Neutral (Confidence: medium)
Earnings Summary
Strides Pharma Science reported steady Q1 FY27 results with 13% YoY revenue growth, driven by strong Ex-US performance (17% YoY). Gross margin expanded 60 bps YoY to 60.9%, but EBITDA margin declined 130 bps YoY due to geopolitical disruptions and higher freight costs. Reported PAT grew 56.7% YoY, including a gain from the Pivot Path divestment. The company is navigating external headwinds with a diversified model. The US business remains soft, but management expects a stronger H2 with new approvals and launches. Capex plans remain disciplined at ₹2.5-3 billion annually.
Management Tone
- Prepared Remarks: Good — Prepared remarks emphasized steady revenue growth of 13% YoY, healthy gross margins, improved PAT, and confidence in long-term strategies despite external headwinds. Management highlighted the resilience of the business model and provided positive forward-looking statements regarding growth drivers.
- Q&A Session: Neutral — Analysts raised questions about softness in the US business, delays in product approvals, and the timing of the controlled substances quota. Management provided detailed responses but acknowledged uncertainties around tariffs, quota allocations, and the Sandoz acquisition close date. The tone was ca
Revenue Growth Drivers
- Strong growth in Ex-US markets, particularly B2C segments in the UK, Nordics, and Africa.
- US business facing increased competition in certain products, impacting revenue growth.
- Supply chain disruptions causing shipment delays in Ex-US markets.
Growth vs Margin Focus
The company emphasizes a balanced approach, focusing on portfolio quality and profitability in the US while pursuing growth in Ex-US markets. The objective is to maintain gross margins in the 58-60% range and deliver superior EBITDA margins, translating into sustained EPS and PAT growth.
About Strides Pharma Science Limited
Strides Pharma Science Limited (STAR) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.